Turning the Spotlight Away from PDT: Chemodynamic Dominance of 2-(2-Bromopyridin-4-yl)-1 H -imidazo[4,5- f ][1,10]phenanthroline Based Ru(II)/Ir(III)/Re(I) Complexes against MDA-MB-231
Journal of Medicinal Chemistry · 25.12.2025 · 68 (24) · 26263-26279
DOI: 10.1021/acs.jmedchem.5c02400 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 07.12.2025. Verfasst von Rishav Das und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, School of Advanced Sciences, Vellore Institute of Technology Vellore 632014, Tamilnadu, India. Hauptthemen laut MEDLINE: Coordination Complexes, Antineoplastic Agents, Phenanthrolines, Photosensitizing Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 66 Literaturangaben. Gefördert von: Council of Scientific and Industrial Research, India, Yenepoya University, Science and Engineering Research Board.
Abstract (Originalsprache)
A series of ruthenium(II), iridium(III), and rhenium(I) complexes incorporating a 2-bromopyridine imidazophenanthroline ligand were synthesized and initially poised as photodynamic therapy candidates, supported by TD-DFT and excited-state lifetime data. Interestingly, cytotoxicity studies in triple negative cancer cells (MDA-MB-231) showed only marginal light-induced effects and low phototoxicity index values; the photodynamic therapeutic potential fell short. In contrast, the ruthenium complex [RuL] delivered striking anticancer activity in the dark, marking a clear shift toward chemodynamic therapy. Ruthenium complexes induced robust ROS generation, mitochondrial membrane disruption, and intrinsic apoptosis, all independent of light. Its mitochondrial localization, G0/G1 arrest, and gene modulation (↑TP53, ↑BAX, and ↓BCL-2) confirmed a mitochondria-targeted CDT mechanism.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Chemistry, School of Advanced Sciences, Vellore Institute of Technology Vellore 632014, Tamilnadu, India.
- Department Stem Cells and Regenerative Medicine Centre, Institution Yenepoya Research Centre, Yenepoya (Deemed to be University), University Road, Derlakatte, Mangalore, Karnataka 575018, India.
- Department of Chemistry, Indian Institute of Technology (BHU), Varanasi, Uttar Pradesh 221005, India.
- Department of Chemistry, Alipurduar University, Alipurduar, 736122 West Bengal, India.
ORCID-Profile: Samya Banerjee, Priyankar Paira
Förderung
- Council of Scientific and Industrial Research, India
- Yenepoya University
- Science and Engineering Research Board
- VIT University
- Department of Science and Technology, Ministry of Science and Technology, India
- Ministry of Education, India
Zitieren
APA
Das, R., Shanavas, S., Das, U., Kushwaha, R., Chakrabarty, R., Banerjee, S., Chaudhury, D., Shenoy P, S., Bose, B., & Paira, P. (2025). Turning the Spotlight Away from PDT: Chemodynamic Dominance of 2-(2-Bromopyridin-4-yl)-1 H -imidazo[4,5- f ][1,10]phenanthroline Based Ru(II)/Ir(III)/Re(I) Complexes against MDA-MB-231. Journal of Medicinal Chemistry, 68(24), 26263-26279. https://doi.org/10.1021/acs.jmedchem.5c02400
Vancouver
Das R, Shanavas S, Das U, Kushwaha R, Chakrabarty R, Banerjee S, et al. Turning the Spotlight Away from PDT: Chemodynamic Dominance of 2-(2-Bromopyridin-4-yl)-1 H -imidazo[4,5- f ][1,10]phenanthroline Based Ru(II)/Ir(III)/Re(I) Complexes against MDA-MB-231. Journal of Medicinal Chemistry. 2025;68(24):26263-26279. doi:10.1021/acs.jmedchem.5c02400
BibTeX
@article{Das2025,
author = {Das, Rishav and Shanavas, Shanooja and Das, Utpal and Kushwaha, Rajesh and Chakrabarty, Rinku and Banerjee, Samya and Chaudhury, Debajit and Shenoy P, S and Bose, Bipasha and Paira, Priyankar},
title = {Turning the Spotlight Away from PDT: Chemodynamic Dominance of 2-(2-Bromopyridin-4-yl)-1 H -imidazo[4,5- f ][1,10]phenanthroline Based Ru(II)/Ir(III)/Re(I) Complexes against MDA-MB-231},
journal = {Journal of Medicinal Chemistry},
year = {2025},
volume = {68},
number = {24},
pages = {26263--26279},
doi = {10.1021/acs.jmedchem.5c02400}
}
EUVIMED